Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, which cancer drugs are currently being considered by Project Orbis.
Answered by Jo Churchill
Information on cancer drugs currently being considered under Project Orbis is considered commercially confidential.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what evidence on transmission the Joint Committee on Vaccination and Immunisation assessed when deciding whether to prioritise household members of immunocompromised clinically extremely vulnerable people in phase two of the covid-19 vaccine programme.
Answered by Nadhim Zahawi
On 30 December 2020, the Joint Committee on Vaccination and Immunisation (JCVI) published its advice on phase one of the COVID-19 vaccination programme. In this advice it stated that consideration had been given to vaccination of household contacts of immunosuppressed individuals. However, at that time there was no data on the size of the effect of COVID-19 vaccines on transmission.
The JCVI is keeping its advice under review, including with regard to emerging evidence on the impact of vaccination on asymptomatic infection and whether this may indicate an impact on transmission. This was last considered at the JCVI’s COVID-19 sub-committee on 4 March 2020 and a position is being agreed with the JCVI’s main committee members.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions (a) he and (b) his officials have had with (i) patients, (ii) patient groups, (iii) special import pharmacies and (iv) prescribing clinicians on the ability to switch at short notice between different medical cannabis products; and if he will make a statement.
Answered by Jo Churchill
From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.
The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.
The Written Ministerial Statement of 26 January (HCWS734) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that children who have their UK prescriptions for medical cannabis dispensed in the Netherlands will continue to receive their medicine after the transition period; and if he will make a statement.
Answered by Jo Churchill
From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.
The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.
The Written Ministerial Statement of 26 January (HCWS734) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether children in Northern Ireland will be able to have their UK prescriptions for medical cannabis dispensed in the Netherlands after the transition period; and if he will make a statement.
Answered by Jo Churchill
From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.
The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.
The Written Ministerial Statement of 26 January (HCWS734) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the Dutch Government on lifting their ban on the export of finished medical cannabis oils; and if he will make a statement.
Answered by Jo Churchill
From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.
The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.
The Written Ministerial Statement of 26 January (HCWS734) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that children who currently have their UK prescriptions for medical cannabis dispensed in the Netherlands will still be able to receive their medicine at the end of the transition period; and if he will make a statement.
Answered by Jo Churchill
From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.
The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.
The Written Ministerial Statement of 26 January (HCWS734) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of children who currently have their UK prescriptions for medical cannabis dispensed in the Netherlands; and if he will make a statement.
Answered by Jo Churchill
From 1 January, United Kingdom prescriptions, including those in Northern Ireland, will no longer be valid in the Netherlands. There are a small number of patients who rely on certain unlicensed cannabis-based medicines that are supplied in the Netherlands against UK prescriptions, almost all of which are private prescriptions.
The Department, supported by the British Embassy to The Hague, has reached an agreement with the Dutch Government to allow the continued supply of Bedrocan oils, a form of unlicensed medicinal cannabis, against United Kingdom prescriptions for existing patients until 1 July 2021. The medicines supply chain has ensured that there continues to be good supply of licensed and unlicensed cannabis-based medicines after the transition period.
The Written Ministerial Statement of 26 January (HCWS734) provided an update on action taken by the Government on supply from the Netherlands and next steps to establish a more permanent solution.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of people who have de-transitioned in each year since 2017.
Answered by Jo Churchill
The National Health Service and the Department do not routinely collect data on the number of people who sought medical intervention to reverse or undo a previous medical intervention for the alleviation of gender dysphoria.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much his Department has spent on consultancy fees for (a) communications, (b) advertising and (c) marketing since 1 March 2020.
Answered by Edward Argar
The Department has spent £9,000 on consultancy fees since 1 March 2020 in respect of communications related activities. This cost reflects the consultancy spend recorded on the digital, engagement and content cost centre. It is possible further communications related consultancy costs have been incurred in other areas of Departmental business however these are not separately identifiable.
In terms of media buying, the Department has spent £10.7 million since 1 March 2020. For spend on communications, advertising and marketing, the information is not collected in the format requested.